LATAM MedTech Insights

Brazil's regulatory agency, ANVISA, has just released a surprise draft guidance for personalized, 3D-printed medical devices, sending shockwaves through the MedTech industry. With a very short 30-day window for public feedback, international companies are now scrambling to understand the complex new rules for software validation and data privacy that could disrupt their market access strategies. T...

In this episode of LATAM MedTech Insights, we dissect the critical regulatory updates from Brazil's ANVISA that are reshaping the landscape for Software as a Medical Device (SaMD). This is not a minor tweak; it's a fundamental shift demanding that foreign manufacturers, especially in the AI and digital health sectors, rethink their entire market entry strategy. We explore the immediate implication...

This week, we dissect the breaking news from Brazil's regulatory landscape. ANVISA has just rolled out RDC 884, a new resolution that specifically targets AI and machine learning-powered medical software. This move signals a profound shift, moving Brazil away from reliance on foreign approvals and establishing a new, sophisticated framework for digital health technology. In this episode, we explor...

This week, we dive into a silent but significant threat to MedTech companies in Brazil: the complexities of ANVISA's registration renewal process. Many manufacturers of Class I and II devices are unaware of the critical differences between a 'Notificação' and a 'Cadastro' approval, leading to a false sense of security. We explore how this simple misunderstanding can lead to the sudden cancellation...

Brazil is tightening its grip on the rapidly growing Software as a Medical Device (SaMD) market. A recent clarification from its regulatory agency, ANVISA, has introduced new, more stringent requirements for clinical evidence and cybersecurity, creating unexpected hurdles for global MedTech innovators. This move, aimed at increasing patient safety, could stall market entry plans for companies unpr...

This week on LATAM MedTech Insights, we dive into the mandatory transition to ANVISA's new digital submission platform in Brazil. While the goal is to accelerate approvals, the reality is a wave of new, technical challenges stalling market access for many MedTech companies. We explore the hidden pitfalls of this digital shift, moving beyond traditional regulatory concerns to the critical importanc...

This week, we dissect a major regulatory shift in Latin America's largest market. Brazil's ANVISA has just launched RDC 987, a new fast-track approval process for AI-powered medical devices. While this promises to slash market entry timelines, it also introduces complex and unprecedented data privacy requirements tied to the LGPD. This episode explores the dual nature of this regulation. It is bot...

In this episode, we dissect the sudden and disruptive launch of ANVISA's new mandatory digital submission platform in Brazil, which has caught many international MedTech manufacturers off guard. We explore the immediate operational challenges, from language barriers to technical glitches, and discuss the strategic implications for companies planning to enter or expand within Latin America's larges...

This week, we dive into the groundbreaking news from Mexico's regulatory agency, COFEPRIS. A new fast-track "equivalency agreement" has been announced, set to revolutionize market access for medical device companies with existing US FDA or European CE Mark approval. This episode unpacks the details of this new pathway, exploring the immense opportunities it creates for international MedTech firms....

This week, we dissect the groundbreaking news from Brazil's ANVISA: a new fast-track approval pathway for AI-powered medical devices. This move promises to slash approval times and revolutionize the digital health landscape, but the opportunities are wrapped in complex new challenges. We go beyond the headlines to explore the intricate new requirements for clinical data, cybersecurity, and local d...

This week, we dive into a major regulatory shift in Brazil that's sending shockwaves through the digital health sector. ANVISA, the national health surveillance agency, has just released RDC 899, a groundbreaking resolution that imposes stringent new cybersecurity and data privacy rules for all Software as a Medical Device (SaMD). This update creates immediate challenges for MedTech companies, esp...

This week on LATAM MedTech Insights, we dissect the latest 2025 medical device registration guidance from Brazil's ANVISA. While the new framework aims to streamline market access, it has introduced a host of undocumented challenges that are causing significant delays for international manufacturers. We explore the gap between the official regulations and the practical hurdles companies are facing...

This week, we dissect the surprise technical note from Brazil's ANVISA that just reshaped the rules for market entry. This clarification to RDC 751 demands more stringent, localized clinical evidence for high-risk devices, creating a significant new hurdle for international MedTech manufacturers looking to enter Latin America's largest market. We explore the immediate impact on companies that have...

Brazil's health agency, ANVISA, has just launched a new digital portal, ending weeks-long delays for essential medical device certificates. This major shift from paper to a fully online system promises to accelerate market access, enhance transparency, and slash the administrative burden that has long frustrated manufacturers trying to enter Latin America's largest market. This episode breaks down...

In this episode of LATAM MedTech Insights, we dissect the chaotic rollout of COFEPRIS's new mandatory digital platform, 'DigiReg'. Launched in the last week of December 2025, this platform was meant to be the final step in simplifying medical device registration in Mexico. Instead, it has created a maze of technical glitches and undocumented requirements. We explore how this "simplification parado...

This episode dives into the most overlooked but critical MedTech trend in Latin America as of late 2025: the dramatic tightening of post-market surveillance rules. While most companies focus on getting their device approved, regulatory bodies like Mexico's COFEPRIS and Brazil's ANVISA have shifted their focus to what happens *after* a product hits the market. We uncover the new requirements for fa...

Mexico's MedTech market is buzzing with the news of COFEPRIS's new fast-track approval pathway, promising quicker market access for devices with existing international approvals. This move positions Mexico as a key entry point into Latin America, attracting significant global interest. However, beneath this promising headline lies a complex new reality. The updated regulations include stringent ne...

This week, we dive into a sudden and seismic regulatory shift in Argentina. ANMAT's newly issued Resolution 785/2025 has introduced strict data localization and cybersecurity audit requirements for all Software as a Medical Device (SaMD) and connected devices, sending shockwaves through the industry. This episode breaks down the immediate implications for foreign manufacturers, who now face a tigh...

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just proposed a new fast-track approval process for AI-driven medical software, promising to slash market entry timelines for devices already approved by agencies like the FDA. But a closer look reveals a complex new challenge that could catch even the most prepared companies off guard. Im...

This week, we dissect a game-changing regulatory shift in Latin America's largest market. Brazil's ANVISA has just launched a new resolution for Software as a Medical Device (SaMD), creating an unprecedented fast-track pathway for innovative digital health products. This move promises to slash approval times and attract global investment. But there's a catch. While the new "fast-track" leverages e...

Last week, Brazil's ANVISA unleashed a pivotal update for Software as a Medical Device (SaMD) with its new resolution, RDC 992/2025. While appearing to align with international standards, this new regulation introduces complex cybersecurity and data privacy requirements tied specifically to Brazil's LGPD law, creating unexpected hurdles for global manufacturers. In this episode of LATAM MedTech In...

This week, we dissect the immediate fallout from ANVISA's surprise regulatory shift in Brazil. While the move towards EU MDR alignment was expected, a hidden clause mandating local usability studies for high-risk devices has caught many international MedTech firms by surprise, threatening to delay launches and inflate budgets. We explore the specifics of the new RDC 987/2025 resolution and what it...

Last week, Brazil's regulatory agency, ANVISA, unveiled a groundbreaking 2025 plan to tackle its notorious medical device approval backlogs. The initiative, named "AnvisAI," leverages artificial intelligence to create an automated fast-track system for lower-risk devices, aiming to cut review times by more than half and reshape the market access landscape. This move signals a major shift, potentia...

This week, we dissect a major regulatory shake-up in Latin America's largest MedTech market: Brazil. ANVISA, the national health surveillance agency, has just initiated a pivotal shift from paper to digital, while simultaneously revoking its traceability regulations. This move promises to cut costs and streamline logistics for manufacturers but introduces a new host of digital compliance and suppl...

Brazil's MedTech landscape is buzzing as its regulatory agency, ANVISA, puts Software as a Medical Device (SaMD) back under the microscope. In its newly released 2024-2025 agenda, ANVISA has signaled major revisions to the existing framework, a move that comes sooner than many in the industry expected. This suggests that the initial guidelines are already being outpaced by rapid advancements in di...